C-Reactive Protein–Triglyceride-Glucose Index and Incident Cardiovascular Disease Stratified by Antihypertensive Medication Use: Evidence from CHARLS

Heart disease remains the leading cause of death worldwide, a relentless force that claims more lives than any other condition. For decades, doctors have known that high blood pressure is a major driver of this damage, yet millions of people live with the condition without ever knowing it or receiving treatment. Beyond blood pressure, scientists have long suspected that the body's internal chemistry plays a crucial role in how arteries age and fail. Two specific processes are often at the heart of this problem: inflammation, which is the body's low-level, chronic response to stress or injury, and metabolic dysfunction, where the body struggles to process sugar and fat efficiently. When these two forces combine, they create a dangerous environment for blood vessels. Researchers have recently developed a way to measure this combined burden using a single number that blends information about inflammation with data on blood sugar and triglycerides, a type of fat found in the blood. This new measure offers a potential window into understanding who is most at risk, especially among the vast number of older adults who have not yet been diagnosed with heart disease or started on medication.

A team of researchers in China set out to test whether this combined measure could predict future heart trouble in a large group of middle-aged and older adults. They turned to a massive, nationally representative survey known as the China Health and Retirement Longitudinal Study, which tracks the health of tens of thousands of people over many years. The scientists focused on a specific calculation that merges levels of C-reactive protein, a marker of inflammation, with fasting blood sugar and triglyceride levels. They wanted to see if people with higher scores on this scale were more likely to already have heart disease or to develop it in the years ahead. Crucially, they also wanted to know if taking medication to lower blood pressure changed how this score worked. In a world where many people are treated for high blood pressure while others are not, understanding whether this new marker works differently for these two groups could help doctors decide who needs closer monitoring.

The researchers analyzed data from over 9,000 participants to look at who already had heart disease at the start of the study, and then followed more than 6,000 of those who were initially healthy for seven years to see who developed new cases. Their findings were clear: a higher score on this combined measure was strongly linked to a greater likelihood of having heart disease at the start, and it also predicted a higher risk of developing heart disease later on. The relationship was steady and direct; as the score went up, the risk went up in a predictable way. People in the highest group of scores were significantly more likely to have heart disease compared to those in the lowest group. This held true even after the researchers accounted for other factors like age, sex, smoking, and body weight. The measure performed slightly better at identifying risk than looking at blood sugar and fat levels alone or looking at inflammation alone, suggesting that the combination provides a more complete picture of the body's struggle.

The study then took a closer look at whether taking blood pressure medication changed the story. When the researchers separated the participants into two groups—those currently taking medication for high blood pressure and those who were not—they noticed a difference in the strength of the connection. The link between the combined score and heart disease appeared stronger and more consistent among the people who were not taking medication. For those who were already on treatment, the connection was weaker and did not reach the same level of statistical certainty. However, the researchers were careful to note that this difference was not a definitive proof that the medication itself erased the risk. It is possible that people on medication are receiving better overall care, including lifestyle advice and other treatments, which might soften the impact of the underlying metabolic issues. It is also possible that the medication itself has protective effects on blood vessels that go beyond just lowering pressure. Because the study did not have detailed records on exactly which drugs people took, how well they followed their prescriptions, or how their health changed over time, the team could not confirm that the medication was the sole reason for the weaker link.

Ultimately, the work suggests that this combined measure is a useful tool for spotting people at risk, particularly those who have not yet entered the medical system for blood pressure control. It highlights that inflammation and metabolic issues often travel together, creating a double burden on the heart. While the measure showed promise, the researchers emphasized that it should be seen as an additional clue rather than a standalone diagnosis. The findings also serve as a reminder that when doctors look at risk markers, they must consider the context of a patient's current treatments. For the millions of older adults living with untreated high blood pressure, a high score on this combined measure could signal a need for earlier and more intensive attention to their heart health. The study does not offer a magic bullet or a simple cure, but it does provide a clearer map of the terrain, showing that the path to heart disease is often paved with both inflammation and metabolic trouble, and that the people walking that path without medical support may be the most vulnerable.